Although the clinical effects of some ROS-inducing drugs were limited, as sulphasalazine in gastric cancer patients [58], other strategies have been favorably tested, e.g., the glutathione disulfide mimetic NOV-002 in patients with HER2-negative breast cancer [59]. Here, ERBB2 is linked to breast carcinoma.